checkAd

     137  0 Kommentare Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) - Seite 3

    For Investor Inquiries:
    Lisa DeFrancesco
    Lexicon Pharmaceuticals, Inc.
    lexinvest@lexpharma.com

    Lesen Sie auch

    For Media Inquiries:
    Alina Cocuzza
    Lexicon Pharmaceuticals, Inc.
    acocuzza@lexpharma.com


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) - Seite 3 The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain in more than 20 years LX9211 has previously …